Literature DB >> 31359191

Frame-based stereotactic biopsy of deep-seated and midline structures in 511 procedures: feasibility, risk profile, and diagnostic yield.

Christina A Hamisch1, Jana Minartz2, Tobias Blau3, Vanessa Hafkemeyer2, Daniel Rueß2, Alexandra Hellerbach2, Stefan J Grau4,5, Maximilian I Ruge2,5.   

Abstract

OBJECTIVES: We evaluated the feasibility, safety, and diagnostic yield of frame-based stereotactic biopsies (SB) in lesions located in deep-seated and midline structures of the brain to analyze these parameters in comparison to other brain areas. PATIENTS AND METHODS: In a retrospective, tertiary care single-center analysis, we identified all patients who received SB for lesions localized in deep-seated and midline structures (corpus callosum, basal ganglia, pineal region, sella, thalamus, and brainstem) between January 1996 and June 2015. Study participants were between 1 and 82 years. We evaluated the feasibility, procedural complications (mortality, transient and permanent morbidity), and diagnostic yield. We further performed a risk analysis of factors influencing the latter parameters. Chi-square test, Student t test, and Mann-Whitney rank-sum test were used for statistical analysis.
RESULTS: Four hundred eighty-nine patients receiving 511 SB procedures (median age 48.5 years, range 1-82; median Karnofsky Performance Score 80%, range 50-100%, 43.8% female/56.2% male) were identified. Lesions were localized in the corpus callosum (29.5%), basal ganglia (17.0%), pineal region (11.5%), sella (7.8%), thalamus (4.3%), brainstem (28.8%), and others (1.1%). Procedure-related mortality was 0%, and permanent morbidity was 0.4%. Transient morbidity was 9.6%. Histological diagnosis was possible in 99.2% (low-grade gliomas 16.2%, high-grade gliomas 40.3%, other tumors in 27.8%, no neoplastic lesions 14.5%, no definitive histological diagnosis 0.8%). Only the pons location correlated significantly with transient morbidity (p < 0.001).
CONCLUSION: In experienced centers, frame-based stereotactic biopsy is a safe diagnostic tool with a high diagnostic yield also for deep-seated and midline lesions.

Entities:  

Keywords:  Deep-seated structures; Diagnostic yield; Feasibility; Midline structures; Safety; Stereotactic biopsy

Mesh:

Year:  2019        PMID: 31359191     DOI: 10.1007/s00701-019-04020-1

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  9 in total

1.  Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD).

Authors:  Truong H Do; Madeleine A Howard; Elise F Palzer; Jared D Huling; Mohammed A Alvi; Samuel W Cramer; Ping Zhu; Reid A Johnson; James Jean; Jinci Lu; Alec B Jonason; Jacob Hanson; Luke Sabal; Kevin W Sun; Robert A McGovern; Clark C Chen
Journal:  J Neurooncol       Date:  2022-07-23       Impact factor: 4.506

2.  Indicators of correct targeting in stereotactic biopsy of intracranial lesions.

Authors:  Osvaldo Vilela-Filho; Jairo Porfírio; Lissa C Goulart
Journal:  Surg Neurol Int       Date:  2022-06-17

3.  Complications after frame-based stereotactic brain biopsy: a systematic review.

Authors:  Maximilien Riche; Aymeric Amelot; Matthieu Peyre; Laurent Capelle; Alexandre Carpentier; Bertrand Mathon
Journal:  Neurosurg Rev       Date:  2020-01-04       Impact factor: 3.042

Review 4.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

Authors:  Michael Weller; Martin van den Bent; Matthias Preusser; Emilie Le Rhun; Jörg C Tonn; Giuseppe Minniti; Martin Bendszus; Carmen Balana; Olivier Chinot; Linda Dirven; Pim French; Monika E Hegi; Asgeir S Jakola; Michael Platten; Patrick Roth; Roberta Rudà; Susan Short; Marion Smits; Martin J B Taphoorn; Andreas von Deimling; Manfred Westphal; Riccardo Soffietti; Guido Reifenberger; Wolfgang Wick
Journal:  Nat Rev Clin Oncol       Date:  2020-12-08       Impact factor: 66.675

5.  Learning Curve Associated with ClearPoint Neuronavigation System: A Case Series.

Authors:  Birra R Taha; Christian R Osswald; Matthew Rabon; Carolina Sandoval Garcia; Daniel J Guillaume; Xiao Wong; Andrew S Venteicher; David P Darrow; Michael C Park; Robert A McGovern; Cornelius H Lam; Clark C Chen
Journal:  World Neurosurg X       Date:  2021-12-16

6.  Stereotactic Biopsy for Brainstem Lesions: A Meta-analysis with Noncomparative Binary Data.

Authors:  Lin He; Dongjie He; Yuhong Qi; Jiejing Zhou; Canliang Yuan; Hao Chang; Qiming Wang; Gaiyan Li; Qiuju Shao
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  A preliminary study of the diagnostic efficacy and safety of the novel boring biopsy for brain lesions.

Authors:  Toshihiro Ogiwara; Junpei Nitta; Yu Fujii; Gen Watanabe; Haruki Kuwabara; Masahiro Agata; Hideki Kobayashi; Yoshinari Miyaoka; Satoshi Kitamura; Yoshiki Hanaoka; Tetsuya Goto; Mai Iwaya; Kazuhiro Hongo; Tetsuyoshi Horiuchi
Journal:  Sci Rep       Date:  2022-03-14       Impact factor: 4.379

8.  Early Surgery Prolongs Professional Activity in IDH Mutant Low-Grade Glioma Patients: A Policy Change Analysis.

Authors:  Pierre A Robe; Matea Rados; Wim G Spliet; Reinier G Hoff; Peter Gosselaar; Marike L D Broekman; Martine J van Zandvoort; Tatjana Seute; Tom J Snijders
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

9.  Evaluation of 311 contemporary cases of stereotactic biopsies in patients with neoplastic and non-neoplastic lesions-diagnostic yield and management of non-diagnostic cases.

Authors:  Krystyna Agnieszka Pasternak; Michael Schwake; Nils Warneke; Max Masthoff; Samer Zawy Alsofy; Eric Suero Molina; Walter Stummer; Stephanie Schipmann
Journal:  Neurosurg Rev       Date:  2020-09-20       Impact factor: 3.042

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.